$EXEL

WYSZOMIERSKI JACK L sold $198K of EXEL

WYSZOMIERSKI JACK L sold 3,925 shares of EXELIXIS, INC. (EXEL) at $50.55 ($0.20M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · WYSZOMIERSKI JACK L
Published Jun 3, 2026, 10:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 10:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EXEL
Neutral
medium confidence
Mentioned
$EXEL
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXELNeutralLow
01

Why it matters

This provides incremental sentiment information but no new fundamental data (no trial, approval, guidance, or deal).

02

Market read

Use mainly for sentiment/positioning checks rather than as a standalone catalyst.

03

What to watch

The filing doesn’t indicate whether additional buys/sells occurred around the same period or whether the director’s plan size is routine versus unusual.

Relevance 6/10Novelty 3/10Timing: Filed June 3; transaction executed June 1 under a 10b5-1 plan.

Background

The article is an SEC Form 4 insider transaction disclosure (director selling shares).

Company-level read

Ticker impact

$EXELNeutralMedium confidence
Context

SEC Form 4 shows an EXELIXIS director sold 3,925 shares in an open-market transaction under a 10b5-1 plan on June 1.

Expected impact

Likely limited/short-lived impact; any reaction should be muted given the pre-arranged 10b5-1 plan.

Evidence & confidence

The filing is a routine insider transaction with a stated pre-arranged 10b5-1 plan, providing disclosure but not a new operating or clinical catalyst.

Market effects

Minimal—this is company-specific insider disclosure without sector-wide regulatory/clinical implications.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 sale, the market may overreact; price action could revert if no other catalysts exist.

Key entities

  • EXELIXIS, INC.

    Company whose director disclosed an open-market sale of shares under a pre-arranged 10b5-1 plan.

Related articles

$EXELHigh

EXELIXIS, INC. (EXEL): Results of Operations and Financial Condition

EXELIXIS, INC. (EXEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 exel20260630exhibit991.htm EX-99.1 Document Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Andrew Peters SVP, Strategy & Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Exelixis Announces

$EXELMed

EXEL Industries: Q3 2025-2026 revenue -18.7%

EXEL Industries reported Q3 FY2025-2026 revenue of €229.2m, down 18.7% year on year, or -18.0% at constant FX and scope, citing lower agricultural equipment volumes. Agricultural Spraying fell 17.1%, Sugar Beet Harvesting 35.6%, Leisure 14.2%, and Industry 16.7%. The company expects no significant cycle recovery before H2 FY2026-2027.

$EXELMedAI 9/10

If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket

Exelixis reported Q1 2026 results that beat consensus, with non-GAAP EPS of $0.87 (up 14.02% vs. expectations) on revenue of $610.81 million (up 9.97% YoY). The company said CABOMETYX franchise revenue rose 12.5% YoY to $764 million and authorized a $750 million buyback through Dec. 31, 2027. Exelixis also has a Dec. 3, 2026 PDUFA decision for zanzalintinib in metastatic colorectal cancer.